Clinical Trial Search

Primary: Myeloperoxidase — 184.3; 66.5; 144.71 g/L

Primary: Cardiac Death — 0; 0 events

Primary: Ischemia Area at Risk as Determined by Paired Single-photon Computed Tomography Studies With Technetium Tc99m Sestamibi.

Primary: Delta Cardiac Troponin I (ΔcTnI) — 0.04; 0.19 ng/mL

Primary: Maximum Increase of Troponin at 24 Hours — 0.478; 0.476 ng/ml

Primary: Infarct Size on Baseline Cardiac Magnetic Resonance Imaging (cMRI) — 20.1; 21.0 ml — p=0.90

Primary: Hospital Mortality Rate — 6; 2 Participants

Primary: Peri-Procedural Myocardial Injury — 23; 29 Participants

Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029

Primary: Area Under the Curve (AUC) of Serum Creatine Kinase Isoenzyme Type Muscle-brain (CK-MB) — 6582.0; 6738.3; 5252.2; 5471.9 ng*hr/mL

Primary: Composite of: Cardiovascular Death*, Re-myocardial Infarct, Re-hospitalization for Heart Failure (HF) and Congestive Heart Failure (CHF), Resuscitation or ICD…

Primary: Number of Patients With ST-segment Elevation Resolution Equal or More Than 50% — 47; 51 participants — p=0.56

Primary: Index of Microcirculatory Resistance — 24.8; 45.0 units

Primary: Number of Death — 417; 137; 552 Participants

Primary: Change in Left Ventricular End Diastolic Volume (LVEDV) — 16.4; 15.8 mL

Primary: Short-termed Fractal Scaling Exponent (Alpha 1) — 0.01; -0.03 unit-less — p=0.34

Primary: Post-op CK-MB Levels — 71.70; 92.66 IU/L — p=<0.05

Primary: Forearm Blood Flow — 6.48; 9.2; 7.32; 8.26 ml/100 ml tissue/min

Primary: C Reactive Protein (Area Under the Curve) — 75.9 mg/L

Primary: Progression of Acute Coronary Syndrome to Myocardial Infarction — 200; 242 participants — p=0.28

Primary: Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction — 255; 295 Participants

Primary: Comparison Between Coronary-artery-disease Group and Non-coronary-artery-disease Group on MIF Concentration — 48.08; 66.79 MIF Concentration,ug/L

Primary: Number of Participants With Contrast Induced-Acute Kidney Injury — 2; 3 participants

Primary: Myocardial Perfusion Reserve — 1.52; 1.94 arbitrary units

Primary: Number of Patients With Acute Kidney Injury — 8; 16 Participants

Primary: Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-systolic Volume Indices — 1.5; 1.0 mL/m2 — p=<0.05

Primary: Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion — 15.1; 17.9; 17.2 Percentage of Left…

Primary: High-Sensitivity Cardiac Troponin Levels From Days 0-7 — 29.2; 17.3; 23.2; 16.7 ng/mL (0-0.04) — p=0.05

Primary: Final Infarct Size — 5; 6 % of LV

Primary: Infarct Size in the Territory of the Infarct Related Artery — 15.8; 15.0 percentage of LV mass